DEA Orders Action Against Physician Hil Rizvi's Practice
Published Date: 10/21/2025
Notice
Summary
Dr. Hil Rizvi from Utah tried to get a DEA registration but got denied because he lied on his application. The DEA found he didn’t tell the truth about important questions, which risks public safety. This decision means Dr. Rizvi won’t get his registration, and the denial is final as of early 2025.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
DEA registration denied for Dr. Hil Rizvi
You (Hil Rizvi, M.D.) had your pending DEA application (Control No. W24074770C) denied. The Order denies that application and any other pending application of yours in Utah, effective November 20, 2025.
Denial based on material falsification of application
DEA found your June 11, 2024 application omitted required details about adverse state licensure actions and concluded those omissions were material under 21 U.S.C. 824(a)(1). The decision identifies omitted actions including West Virginia revocation (Aug 17, 1999), Vermont suspension (Sept 2, 1999), New Hampshire revocation (Jan 13, 2021), Oklahoma denial (Sept 14, 2023), and New Mexico denial (May 10, 2023), and relies on those omissions to deny the application.
Applicant found in default; hearing rights waived
The DEA found you in default for failing to timely request or properly file a hearing under 21 CFR 1301.43 after the Order to Show Cause, and you waived your right to a hearing. Because of that default, the factual allegations in the OSC were deemed admitted and formed the basis for the final denial.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-16665, Exempt Chemical Preparations Under the Controlled Substances Act
The applications for exempt chemical preparations received by the Drug Enforcement Administration between March 1, 2026, and June 30, 2026, as listed below, were accepted for filing and have been approved or denied as indicated. This publication addresses preparations through June 30, 2026, that were not included in previous Federal Register notices, and it does not affect preparations that have been previously published.
2026-16413, Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I
The Drug Enforcement Administration issues this temporary order to schedule O-desmethyltramadol (other names: O-DSMT; desmetramadol; 3-[(1R,2R)-2-[(dimethylamino)methyl]-1- hydroxycyclohexyl]phenol), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, in schedule I of the Controlled Substances Act. DEA bases this action on a finding that placing O-DSMT in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle O-DSMT.
2026-16375, Schedules of Controlled Substances: Rescheduling of Suvorexant, Lemborexant, and Daridorexant From Schedule IV Into Schedule V
The Drug Enforcement Administration proposes to transfer suvorexant ([(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4- diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone), lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)- N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide), and daridorexant ([(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1- yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone) from schedule IV to schedule V of the Controlled Substances Act. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule V controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle suvorexant, lemborexant, and daridorexant.
2026-15624, Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical
The Drug Enforcement Administration is proposing to modify the listing of the list I chemical 3,4-MDP-2-P methyl glycidic acid (also known as PMK glycidic acid) to include esters of 3,4-MDP-2-P methyl glycidic acid, not listed elsewhere in the Controlled Substances Act (CSA), as list I chemicals under the CSA. The current listing of 3,4- MDP-2-P methyl glycidic acid includes its salts, optical and geometric isomers, and salts of isomers. DEA proposes the new listing to read as follows: 3,4-MDP-2-P methyl glycidic acid (PMK glycidic acid) and its esters, not listed elsewhere in the CSA, its optical and geometric isomers, its salts, salts of its optical and geometric isomers, salts of its esters, not listed elsewhere in the CSA, and any combination thereof, whenever the existence of such is possible.
Previous / Next Documents
Previous: 2025-19611, Enyibuaku Uzoaga, M.D.; Decision and Order
Dr. Enyibuaku Uzoaga received an important decision that affects their professional status. This order changes how certain rules apply to them, with clear deadlines to follow and possible financial effects. If you’re connected to Dr. Uzoaga’s work, keep an eye on the timing and details to stay on track!
Next: 2025-19613, MCRGC, LLC; Decision and Order
MCRGC, LLC wanted to grow marijuana but didn’t have the right licenses, a real location, or proper agreements, so the DEA said no to their application. Since MCRGC didn’t ask for a hearing or fix these issues, their request got denied for good. This means MCRGC can’t legally grow marijuana, and anyone applying must have all paperwork and approvals in place to avoid the same fate.